<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04053361</url>
  </required_header>
  <id_info>
    <org_study_id>GH-18-02-00027-0-202</org_study_id>
    <nct_id>NCT04053361</nct_id>
  </id_info>
  <brief_title>Catheter Ablation of Atrial Fibrillation in Patients With Pulmonary Hypertension Hypertension: a Randomised Study</brief_title>
  <official_title>Catheter Ablation of Atrial Fibrillation/Tachycardia in Patients With Pulmonary Hypertension: a Randomised Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General University Hospital, Prague</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>General University Hospital, Prague</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation (AF) and atrial tachycardia (AT), including type I atrial flutter, are
      frequently observed in patients with pulmonary hypertension (PH). Catheter ablation of AF /
      AT has been established as an effective treatment option in selected patients. However,
      little is known about the efficacy and safety of this approach in patients with PH. It has
      also been shown that considerable proportion of patients with PH after acutely successful
      catheter ablation suffer from the recurrence of clinical or newly manifested arrhythmia. We
      propose a prospective study to compare two ablation strategies in a randomized fashion:
      radiofrequency catheter ablation targeting only the clinical arrhythmia versus more extensive
      substrate-based catheter ablation. This project will investigate the clinical outcome of
      patients with pulmonary hypertension and symptomatic atrial fibrillation / tachycardia who
      will be randomly allocated to selective versus complex radiofrequency catheter ablation of
      arrhythmogenic substrate.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arrhythmia recurrence</measure>
    <time_frame>3 months</time_frame>
    <description>Documented arrhythmia recurrence &gt;30 s without antiarrhythmic drugs in post-blanking period after the index ablation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>On-drugs arrhythmia recurrence</measure>
    <time_frame>3 months</time_frame>
    <description>Documented on-drugs arrhythmia recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptoms of arrhythmia</measure>
    <time_frame>3 months</time_frame>
    <description>Symptoms of arrhythmia by questionare</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>EQ5D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>3 months</time_frame>
    <description>Mortality of any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure-related complication rate</measure>
    <time_frame>1 day (Once)</time_frame>
    <description>Complications related to catheter ablation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reablation</measure>
    <time_frame>3 months</time_frame>
    <description>Number of repeat catheter ablations if symptoms are ongoing</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>Group A: Clinical ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Cinical arrhythmia is fairly documented AF, pulmonary vein isolation will be performed. If AF persists after this step, electrical cardioversion will be performed.
If clinical arrhythmia is fairly documented type 1 AFL, cavo-tricuspid isthmus ablation will be performed.
If clinical arrhythmia is AT, it will be induced (if not persistent), identified by means of activation and/or entrainment mapping, and ablated.
If clinical arrhythmia is AT that is non-inducible during EP study, no ablation will be done.
If other incidental (or induced) AT is observed that can be qualified as non-clinical it will not be targeted unless considered important to ablate at discretion of operator.
No induction protocols for other, on top of already ablated, arrhythmias will be attempted.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: Clinical plus substrate-based ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>- The initial ablation steps will be identical to those in patients from Group A.
Supplemental ablation will consist of:
Empirical lesion set within right atrium: superior vena cava isolation, posteroseptal bicaval line, and cavo-tricuspid isthmus ablation (if not already ablated)
AND
Homogenization of low-voltage zones (if any) in left / right atrium defined by bipolar voltage &lt;0.5 mV in sinus rhythm or &lt;0.2 mV in AF / AT. The threshold can be adapted in severely diseased atria to delineate reasonably smaller zones (&lt;20% of atrial surface) achievable to ablate.
Arrhythmia induction protocol by10-second burst atrial pacing with cycle length of 300 ms decremented by 10 ms up to atrial refractoriness or cycle length of 200 ms.
Inducible ATs will be mapped and ablated if feasible. In case of inducible persistent (&gt;5 min) AF, pulmonary vein isolation will be performed if not previously done as per protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Catheter ablation</intervention_name>
    <description>Catheter ablation of atrial fibrillation or atrial tachykardie related to atrial fibrillation with use of radiofrequency energy.</description>
    <arm_group_label>Group A: Clinical ablation</arm_group_label>
    <arm_group_label>Group B: Clinical plus substrate-based ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pre-capillary PH (PAMP ≥25 mmHg; PAWP ≤15 mmHg) or combined post- a pre-capillary PH
             (PAMP ≥25 mmHg; PAWP &gt;15 mmHg; DPG ≥7 mmHg and/or PVR &gt;3 W.u.) of any etiology.

        Exclusion Criteria:

          -  Complex congenital heart defects (corrected or uncorrected)

          -  Isolated post-capillary PH (PAMP ≥25 mmHg; PAWP &gt;15 mmHg; DPG &lt;7 mmHg and/or PVR ≤
             3W.u.)

          -  Previous catheter ablation for AF / AT / AFL

          -  Previous or scheduled cardiac surgery-

          -  NYHA Class IV, cardiogenic shock

          -  Life expectancy &lt;1 year

          -  Non-compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stepan Havranek, M.D.</last_name>
    <phone>+420723085848</phone>
    <email>stepan.havranek@vfn.cz</email>
  </overall_contact>
  <location>
    <facility>
      <name>FN Olomouc</name>
      <address>
        <city>Olomouc</city>
        <zip>77900</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomas Skala</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IKEM</name>
      <address>
        <city>Prague</city>
        <zip>10000</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Wichterle</last_name>
      <phone>+420224963418</phone>
      <email>wichterle@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>General University Hospital in Prague</name>
      <address>
        <city>Prague</city>
        <zip>12808</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stepan Havranek</last_name>
      <phone>+420723085848</phone>
      <email>stepan.havranek@centrum.cz</email>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>June 28, 2019</study_first_submitted>
  <study_first_submitted_qc>August 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2019</study_first_posted>
  <last_update_submitted>August 9, 2019</last_update_submitted>
  <last_update_submitted_qc>August 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>General University Hospital, Prague</investigator_affiliation>
    <investigator_full_name>Stepan Havranek</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Pulmonary Hypertension</keyword>
  <keyword>Catheter Ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

